Eupraxia Pharmaceuticals Inc.

NASDAQ:EPRX

Biotechnology

Healthcare
$6.21 +1.11%

+$0.07 today

Market cap
$417.57M
Beta
1.48
P/E (TTM)
-8.5
EPS (TTM)
-$0.74
52W Low $4.19High $9.32

Volume 1.21M

Average 0.22M

EPRX Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Eupraxia Pharmaceuticals Inc.NASDAQ: EPRX

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity rises 405.4% from a year ago

Total equity stood at $136.64M at the end of Q1 FY2026, up 405.4% from a year earlier and up 69.8% from the prior quarter. Over 3 fiscal years it compounded at +102.0% a year.

Context

  • Total equity amounted to 93.7% of total assets at the end of Q1 FY2026, up 1.2 pp from a year earlier.
  • Total equity increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +405.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$136.64M+69.8% QoQ
Last fiscal yearDec 2025
$80.45M+152.7% YoY
Year agoMar 2025
$27.03M+405.4% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+405.4%——
1 year+152.7%——
3-year CAGR+102.0%——
5-year CAGR——
10-year CAGR——

Total Equity history

Mixed currencies · from the balance sheet

Latest · FY2025
80.45M USD
Year-over-year change
+152.7%

Total Equity vs competitors

How EPRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +405.4% is the highest of 10, against a peer median of +14.3%.
  • Total equity amounts to 93.7% of total assets for EPRX, versus a peer median of 81.2%.
EPRX Competitors
Total Equity for EPRX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
TARAProtara Therapeutics, Inc.Mar 2026$181.21M USD+14.3%+24.4%94.4%
NAUTNautilus Biotechnology, Inc.Mar 2026$144.42M USD-25.7%-20.7%81.2%
EPRXEupraxia Pharmaceuticals Inc.Mar 2026$136.64M USD+405.4%+102.0%93.7%
SLSSELLAS Life Sciences Group, Inc.Sep 2026$131.81M USD+188.9%+144.5%93.4%
AARDAardvark Therapeutics, Inc. Common StockMar 2026$86.99M USD-42.3%—88.2%
OBIOOrchestra BioMed Holdings, Inc.Mar 2026$50.97M USD+202.3%+6.5%50.6%
MDWDMediWound Ltd.Mar 2026$41.42M USD+32.5%+58.7%51.8%
NTHINeonc Technologies Holdings, Inc.Mar 2026-$13.23M USD-37.5%—397.3%
IVAInventiva S.A.Dec 2025-€29.04M EUR+72.8%—11.7%
RNACCartesian Therapeutics, Inc.Mar 2026-$148.12M USD-579.8%—51.4%
Peer median (excluding EPRX) —+14.3%+24.4%81.2%

Competitors are the stored peer set for EPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · USD
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Cash & Equivalents20.89M24.73M14.56M33.1M80.56M
Short-term Investments9.01M0000
Net Receivables00143.52K228.87K674.23K
Inventory00000
Other Current Assets429.72K121.47K000
Total Current Assets30.6M25.17M14.91M34.44M85.1M
Property, Plant & Equipment (Net)589.07K718.61K343.52K424.92K987.13K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets31.37K3.37K5.2K80.76K64.33K
Total Non-current Assets620.44K721.98K348.72K505.68K1.05M
Total Assets31.22M25.89M15.26M34.94M86.15M
Account Payables00000
Short-term Debt94.92K107.53K7.83M078.31K
Tax Payables0027.42K00
Deferred Revenue00000
Other Current Liabilities5.01K21.66K646.48K1.49M(78.31K)
Total Current Liabilities2.27M4.14M14.59M3.1M5.63M
Long-term Debt9.7M11.92M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities9.84M11.99M0075.91K
Total Liabilities12.1M16.13M14.59M3.1M5.7M
Common Stock77.65M96.13M69.96M116.36M195.41M
Retained Earnings(74.26M)(104.63M)(79.43M)(131M)(169.58M)
Accumulated OCI16.56M(3.77M)(2.04M)(4.16M)(2.04M)
Other Stockholders Equity0(931)000
Minority Interest(833.84K)(783.49K)(996.78K)(1.57M)(1.6M)
Total Equity19.12M9.76M671.86K31.84M80.45M
Total Debt9.99M12.17M7.87M71.86K154.36K
Net Debt(10.9M)(12.56M)(6.69M)(33.03M)(80.41M)

Eupraxia Pharmaceuticals Inc.

NASDAQ:EPRX

Intrinsic Alpha fair value

Locked

Current Price

$6.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.